Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term sibeprenlimab treatment in IgA nephropathy (Phase 2/3 rollover)
2023-507233-19-00Phase 3Authorised
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, open-label, single-arm trial of sibeprenlimab in IgA nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability. Planned start Feb 2023; status: authorised.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2023-507233-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507233-19-00.